These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35895050)

  • 1. Perspectives on Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian Cancer.
    Jastrzebski T
    JAMA Surg; 2022 Oct; 157(10):970. PubMed ID: 35895050
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives on Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian Cancer.
    Bhatt A; Bhandoria G; Glehen O
    JAMA Surg; 2022 Oct; 157(10):969-970. PubMed ID: 35895071
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives on Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian Cancer-Reply.
    Lim MC; Park B; Park SY
    JAMA Surg; 2022 Oct; 157(10):970-971. PubMed ID: 35895070
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer.
    Mutlu Sütcüoğlu B; Sütcüoğlu O
    Lancet Oncol; 2023 Dec; 24(12):e457. PubMed ID: 38039999
    [No Abstract]   [Full Text] [Related]  

  • 5. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer - Authors' reply.
    Aronson SL; Sonke GS; van Driel WJ
    Lancet Oncol; 2023 Dec; 24(12):e458. PubMed ID: 38040000
    [No Abstract]   [Full Text] [Related]  

  • 6. Hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: current evidence-based indications.
    Pareja R
    Int J Gynecol Cancer; 2023 May; 33(5):841-842. PubMed ID: 36963802
    [No Abstract]   [Full Text] [Related]  

  • 7. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
    Schwameis R; Chiva L; Harter P
    Int J Gynecol Cancer; 2022 Apr; 32(4):578. PubMed ID: 35121632
    [No Abstract]   [Full Text] [Related]  

  • 8. The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer.
    Brennan DJ; Driel WJV; Zivanovic O
    Int J Gynecol Cancer; 2023 May; 33(5):851-852. PubMed ID: 36898700
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: long-term findings from the OVHIPEC-1 trial.
    Ghirardi V; Fagotti A; Scambia G
    Lancet Oncol; 2023 Oct; 24(10):1057-1059. PubMed ID: 37797627
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.
    Wethington SL; Armstrong DK; Johnston FM
    JAMA Surg; 2022 May; 157(5):383. PubMed ID: 35262650
    [No Abstract]   [Full Text] [Related]  

  • 11. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.
    Vos LMC; Aronson SL; van Driel WJ; Huitema ADR; Schagen van Leeuwen JH; Lok CAR; Sonke GS
    Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():86-102. PubMed ID: 34565676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Debatable Role of HIPEC in Ovarian Cancer.
    Paulino E; Melo AC
    Ann Surg Oncol; 2022 May; 29(5):3353-3354. PubMed ID: 35254576
    [No Abstract]   [Full Text] [Related]  

  • 13. HIPEC in the Consolidation Setting: A Consolation Prize for Chemorefractory Ovarian Cancer?
    Dellinger TH
    Ann Surg Oncol; 2023 Jun; 30(6):3177-3179. PubMed ID: 36811736
    [No Abstract]   [Full Text] [Related]  

  • 14. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?
    Alter R; Turaga K; Lengyel E
    JAMA Netw Open; 2020 Aug; 3(8):e2014184. PubMed ID: 32840618
    [No Abstract]   [Full Text] [Related]  

  • 15. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    Kim SI; Kim JW
    ESMO Open; 2021 Jun; 6(3):100149. PubMed ID: 33984680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial".
    Noiret B; Bakrin N; Eveno C
    Ann Surg Oncol; 2022 May; 29(5):3357-3358. PubMed ID: 35192155
    [No Abstract]   [Full Text] [Related]  

  • 17. Intraperitoneal chemotherapy: Hot, timely, and relevant?
    Mackay HJ; Kohn EC
    Cancer; 2020 Dec; 126(24):5206-5209. PubMed ID: 32931026
    [No Abstract]   [Full Text] [Related]  

  • 18. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.
    Cascales Campos PA; González Gil A
    Ann Surg Oncol; 2022 May; 29(5):3361-3362. PubMed ID: 35254577
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic significance of ovarian metastases (macroscopic or microscopic) in patients with colorectal cancer undergoing cytoreduction followed by HIPEC.
    Iavazzo C; Spiliotis J
    Int J Colorectal Dis; 2020 Jul; 35(7):1335-1336. PubMed ID: 32363478
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control.
    Petrillo M; Anchora LP; Scambia G; Fagotti A
    Oncologist; 2016 May; 21(5):532-4. PubMed ID: 27009941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.